News

Kaneq Bioscience was created for developing a protein tyrosine phosphatase1B (PTP-1B) inhibitor, designed for treating type 2 diabetes mellitus. Kaneq Pharma CEO Daniel Bouthillier said other approaches targeting

The agreement allows Dezima to in-license CETP inhibitor from Mitsubishi Tanabe Pharma and supports the advancement of DEZ-001 into Phase 3 trials. Professor John Kastelein, founder of Dezima,

The Nijmegen facility will produce ADCs, which combine specific anti-cancer antibody or antibody fragment to an anti-cancer therapeutic, required for Phase III trials and early launches. Company has

The land-based aquaculture system is designed to support multiple generations of all stages of Megathura crenulata’s life cycle, producing pharmaceutical grade KLH in commercial scale. Stellar president and

The research is focused on identifying biomarkers, non-ambulatory endpoints in duchenne muscular dystrophy. Funds will allow recruitment of 100 additional subjects and expand the study through the 20

Treatment methods with IL-17E include single and combination therapy along with anticancer drugs such as gemcitabine, paclitaxel, docetaxel, erlotinib, cisplatin and bevacizumab. Patent also protects the treatment of

Levonorgestrel and Ethinyl Estradiol Tablets are the generic equivalent to Watson Laboratories’ Lutera 28 tablets indicated to prevent pregnancy in women. Lupin is expected to begin the product

The 13C- and 15N-labeled phytochemicals and plant products can be used in food & beverage, nutraceutical, pharmaceutical, cosmeceutical and environmental sciences research as tracers and internal standards. ChromaDex

Adaptimmune will make use of PCT services in the development of its NYESO-1c259-T cell therapy targeting various oncology indications. Adaptimmune chief executive officer James Noble said, "With our